Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Bone

• Publication date

  2005-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.BONE.2004.12.015PMID 15781001
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Polymorphisms of the interleukin-6 gene are associated with bone mineral density

  2006cited by this paper
• Serum osteoprotegerin as a determinant of bone metabolism in a longitudinal study of human pregnancy and lactation.

  2003cited by this paper
• Osteoprotegerin Levels in Primary Hyperparathyroidism: Effect of Parathyroidectomy and Association with Bone Metabolism

  2003cited by this paper
• Genetic determinants of susceptibility to osteoporosis.

  2003cited by this paper
• Role of RANK ligand in mediating increased bone resorption in early postmenopausal women.

  2003cited by this paper
• Twin study of genetic and environmental influences on glucose tolerance and indices of insulin sensitivity and secretion

  2003cited by this paper
• Circulating osteoprotegerin in women during GnRH-agonist treatment and their relationships with mineral components and biomarkers of bone turnover.

  2003cited by this paper
• Age-related changes in cortical bone content of insulin-like growth factor binding protein (IGFBP)-3, IGFBP-5, osteoprotegerin, and calcium in postmenopausal osteoporosis: a cross-sectional study.

  2003cited by this paper
• Polymorphisms in the transforming growth factor beta 1 gene and osteoporosis.

  2003cited by this paper
• A Common Methylenetetrahydrofolate Reductase (C677T) Polymorphism Is Associated With Low Bone Mineral Density and Increased Fracture Incidence After Menopause: Longitudinal Data From the Danish Osteoporosis Prevention Study

  2003cited by this paper
• Theory and practice in quantitative genetics.

  2003cited by this paper
• A single nucleotide polymorphism in the promoter region of the human gene for osteoprotegerin is related to vascular morphology and function.

  2002cited by this paper
• Mapping of Quantitative Ultrasound of the Calcaneus Bone to Chromosome 1 by Genome-Wide Linkage Analysis

  2002cited by this paper
• Association of Polymorphisms of the Estrogen Receptor α Gene With Bone Mineral Density and Fracture Risk in Women: A Meta‐Analysis

  2002cited by this paper
• Effects of the Natural and Artificial Menstrual Cycle on the Production of Osteoprotegerin and the Bone Resorptive Cytokines IL-1b and IL-6

  2002cited by this paper
• Correlates of Osteoprotegerin Levels in Women and Men

  2002cited by this paper
• Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women.

  2002cited by this paper
• Polymorphisms in the Osteoprotegerin Gene Are Associated With Osteoporotic Fractures

  2002cited by this paper
• Genetic Variation in Bone Mineral Density and Calcaneal Ultrasound: A Study of the Influence of Menopause Using Female Twins

  2001cited by this paper
• Cigarette smoking, alcohol consumption, and risk of hip fracture in women.

  2001cited by this paper
• Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women.

  2001cited by this paper
• Genome Screen for Quantitative Trait Loci Underlying Normal Variation in Femoral Structure

  2001cited by this paper
• The validity of twin studies

  2000cited by this paper
• Association of Methylenetetrahydrofolate Reductase (MTHFR) Polymorphism with Bone Mineral Density in Postmenopausal Japanese Women

  2000cited by this paper
• Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis

  2000cited by this paper
• OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

  1999cited by this paper
• Immunological Characterization of Circulating Osteoprotegerin/Osteoclastogenesis Inhibitory Factor: Increased Serum Concentrations in Postmenopausal Women with Osteoporosis

  1999cited by this paper
• Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin.

  1998cited by this paper
• Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone.

  1998cited by this paper
• Tumor necrosis factor-alpha and -beta upregulate the levels of osteoprotegerin mRNA in human osteosarcoma MG-63 cells.

  1998cited by this paper
• Osteoprotegerin mRNA is increased by interleukin-1 alpha in the human osteosarcoma cell line MG-63 and in human osteoblast-like cells.

  1998cited by this paper
• Tumor Necrosis Factor-α and -β Upregulate the Levels of Osteoprotegerin mRNA in Human Osteosarcoma MG-63 Cells

  1998cited by this paper
• Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast.

  1998cited by this paper
• Transforming Growth Factor-β1 Increases mRNA Levels of Osteoclastogenesis Inhibitory Factor in Osteoblastic/Stromal Cells and Inhibits the Survival of Murine Osteoclast-like Cells

  1998cited by this paper
• osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.

  1998cited by this paper
• Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.

  1998cited by this paper
• Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro.

  1998cited by this paper
• Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids.

  1998cited by this paper
• Transforming growth factor-beta1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells.

  1998cited by this paper
• Familial resemblance for bone mineral mass is expressed before puberty.

  1998cited by this paper
• Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.

  1998cited by this paper
• Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

  1997cited by this paper
• Polymorphisms of the interleukin-6 gene are associated with bone mineral density.

  1997cited by this paper
• Reduced bone density and osteoporosis associated with a polymorphic Sp1 binding site in the collagen type I α 1 gene

  1996cited by this paper
• The bone density of female twins discordant for tobacco use.

  1994cited by this paper
• Family history of osteoporosis and bone mineral density at the axial skeleton: The rancho bernardo study

  1994cited by this paper
• Prediction of bone density from vitamin D receptor alleles

  1994cited by this paper
• Is heritability a risk factor for postmenopausal osteoporosis?

  1992cited by this paper
• Methodology for Genetic Studies of Twins and Families

  1992cited by this paper
• Familiality and partitioning the variability of femoral bone mineral density in women of child-bearing age

  1992cited by this paper
• Genetic determinants of bone mass in adult women: A reevaluation of the twin model and the potential importance of gene interaction on heritability estimates

  1991cited by this paper
• Genetic determinants of bone mass in adults. A twin study.

  1987cited by this paper
• Printed in U.S.A. Copyright © 1999 by The Endocrine Society Parathyroid Hormone Stimulates TRANCE and Inhibits Osteoprotegerin Messenger Ribonucleic Acid Expression in Murine Bone Marrow Cultures: Correlation with

  year unknowncited by this paper

• Correlates of circulating osteoprotegerin in women with a pathogenic or likely pathogenic variant in the BRCA1 gene.

  2023cites this paper
• Delineating the role of osteoprotegerin as a marker of breast cancer risk among women with a BRCA1 mutation

  2022cites this paper
• Clinical Data for Parametrization of In Silico Bone Models Incorporating Cell-Cytokine Dynamics: A Systematic Review of Literature

  2022influential citation
• Regulation of TNF-Induced Osteoclast Differentiation

  2021cites this paper
• Pharmacological mechanisms of therapeutics

  2020cites this paper
• Serum RANKL, osteoprotegerin (OPG) and RANKL/OPG ratio in children with systemic lupus erythematosus

  2019cites this paper
• Reproductive and Lifestyle Factors and Circulating sRANKL and OPG Concentrations in Women: Results from the EPIC Cohort

  2019cites this paper
• Osteoclast Signal Transduction Pathways: The RANKL/RANK System

  2019cites this paper
• Osteoprotegerin, Receptor Activator of Nuclear Factor Kappa B Ligand, and Growth Hormone/Insulin-Like Growth Factor-1 Axis in Children with Growth Hormone Deficiency.

  2018cites this paper
• Cardiovascular disease and bone loss—new research in identifying common disease pathophysiologies and predictors

  2018cites this paper
• Premenopausal Trabecular Bone Loss is Associated with a Family History of Fragility Fracture

  2016cites this paper
• Different health behaviours and clinical factors associated with bone mineral density and bone turnover in premenopausal women with and without type 1 diabetes

  2015cites this paper
• Family resemblance of bone turnover rate in mothers and daughters—the MODAM study

  2015cites this paper
• Meta-analysis of genome-wide association studies identifies two loci associated with circulating osteoprotegerin levels.

  2014cites this paper
• Changes in serum RANKL and OPG with sexual development and their associations with bone turnover and bone mineral density in a cohort of girls.

  2014cites this paper
• Twins and endocrinology

  2014cites this paper
• Insulin-Like Growth Factor-1 and Osteocalcin Are Correlated with Markers of Osteoporosis in Postmenopausal Women with Type-2 Diabetes

  2013cites this paper
• OPG and sRANKL serum levels and incident hip fracture in postmenopausal Caucasian women in the Women's Health Initiative Observational Study.

  2013cites this paper
• Melatonin impairs fracture healing by suppressing RANKL-mediated bone remodeling.

  2012cites this paper
• Osteoprotegerin is associated with hip fracture incidence: the Tromso Study.

  2012cites this paper
• Relationship between serum RANKL and RANKL in bone

  2011cites this paper
• Heritability of Serum Osteoprotegerin

  2011influential citation
• The Danish Twin Registry

  2011cites this paper
• Serum osteoprotegerin levels are related to height loss: The Tromsø Study

  2011cites this paper
• Serum osteoprotegerin correlates with age and bone mass in postmenopausal, but not in fertile age women.

  2011cites this paper
• Levels of osteoprotegerin (OPG) and receptor activator for nuclear factor kappa B ligand (RANKL) in serum: Are they of any help?

  2010cites this paper
• Bone Reversal Effects of Plant Bioactive Compounds in Postmenopausal Women

  2010cites this paper
• Serum RANKL, osteoprotegerin (OPG), and RANKL/OPG ratio in nephrotic children

  2010cites this paper
• Bone loss in relation to serum levels of osteoprotegerin and nuclear factor-κB ligand: the Tromsø Study

  2010influential citation
• Viewpoint: Dried plum, an emerging functional food that may effectively improve bone health

  2009cites this paper
• One Year of Transgenic Overexpression of Osteoprotegerin in Rats Suppressed Bone Resorption and Increased Vertebral Bone Volume, Density, and Strength

  2009cites this paper
• Circulating profiles of osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in post-menopausal women

  2008cites this paper
• Skeletal deterioration induced by RANKL infusion: a model for high-turnover bone disease

  2008cites this paper
• Is A163G polymorphism in the osteoprotegerin gene associated with heel velocity of sound in postmenopausal women?

  2008cites this paper
• Vitamin K, circulating cytokines, and bone mineral density in older men and women.

  2008cites this paper
• Circulating Osteoprotegerin and Soluble RANK Ligand in Systemic Sclerosis

  2008influential citation
• EFECTOS DEL TABAQUISMO SOBRE LOS NIVELES PLASMATICOS DE OSTEOPROTEGERINA EN ADULTOS JOVENES SANOS

  2008cites this paper
• Insights in the application of research-grade diagnostic kits for biomarker assessments in support of clinical drug development: bioanalysis of circulating concentrations of soluble receptor activator of nuclear factor kappaB ligand.

  2008cites this paper
• Serum levels of receptor activator of nuclear factor kappaB ligand (RANKL) in healthy women and men.

  2007cites this paper
• The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study.

  2007cites this paper
• No associations between OPG gene polymorphisms or serum levels and measures of osteoporosis in elderly Australian women.

  2007cites this paper
• Bone structure and metabolism in a rodent model of male senile osteoporosis.

  2007cites this paper
• Osteoprotegerin and RANKL Serum Levels and Their Relationship with Serum Ghrelin in Children with Chronic Renal Failure and on Dialysis

  2007cites this paper
• OPG, RANK-L, bone metabolism, and BMD in patients on peritoneal dialysis and hemodialysis.

  2006cites this paper
• Age of donor alters the effect of cyclic hydrostatic pressure on production by human macrophages and osteoblasts of sRANKL, OPG and RANK

  2006cites this paper
• Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength.

  2005cites this paper
• Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism.

  2004cites this paper
• Opg and Srankl Serum Levels and Incident Hip Fracture in Postmenopausal Caucasian Women in the Women's Health Initiative Observational Study

  year unknowncites this paper